Ampa One Collaborating with Wave Neuroscience's EEG-based MeRT® Treatment Prescriptions Under New Partnership

Integration will allow clinics to run Wave Neuroscience's MeRT software on Ampa's portable, subscription-based TMS system

PALO ALTO, Calif., Nov. 10, 2026 /PRNewswire/ -- Ampa, the neurotechnology company that makes Ampa One, a portable transcranial magnetic stimulation (TMS) system, and Wave Neuroscience, developer of the MeRT® System cleared for PTSD, today announced a commercial partnership with the intent to integrate MeRT with Ampa One. Clinics that license Wave Neuroscience's MeRT System, which is FDA-cleared for PTSD, will be able to deliver MeRT treatment using the Ampa One systems they already have.

Ampa One is a portable TMS system offered on subscription with no upfront capital cost, and it uses built-in camera guidance to confirm coil position. Wave Neuroscience's MeRT System uses EEG-derived biomarkers to personalize TMS stimulation parameters. Their platform is FDA-cleared for the treatment of PTSD. Because Ampa One is a subscription, clinics will be able to add MeRT without needing to purchase a TMS system.

"If MeRT is part of your plan and you're choosing a TMS system now, Ampa One belongs on the list. Clinics that sign with us now will be able to add MeRT when the integration is complete." said Ampa Founding Executive, Itamar Kandel.

Brent Bellm, Chief Commercial Officer at Wave Neuroscience, noted, "Wave's MeRT® System enhances TMS by personalizing the treatment pulse rate to each patient's brain. Using EEG/ECG-derived biomarkers and proprietary algorithms, MeRT® introduces a new model of objectivity, transparency, and precision to the delivery of TMS. We recognize Ampa One as an innovator in TMS product design, pricing, and protocols, and we look forward to integrating MeRT® with Ampa One to expand access for the 13 million US adults suffering from PTSD."

To get updates on MeRT availability for Ampa One, clinics can register here.

About Ampa

Ampa is a neurotechnology company that makes Ampa One, a general purpose, portable transcranial magnetic stimulation (TMS) system cleared by the U.S. Food and Drug Administration for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication. Ampa One is available by prescription only. Offered to clinics on a monthly subscription with no capital purchase and no per-treatment fee, Ampa One is built by clinicians for clinicians to make TMS more accessible, portable and easy-to-use. Founded by researchers who helped pioneer modern TMS protocols, Ampa's mission is to enable one billion remissions from mental and neurological disorders. Learn more at www.ampahealth.com.

About Wave Neuroscience 

Wave Neuroscience is a leader in personalized non-invasive neuromodulation technology focused on advancing precision brain health for neurological and mental health conditions. The company's proprietary MeRT® platform combines EEG-based brain analysis with individualized neuromodulation protocols designed to recommend TMS treatment parameters based on each patient's unique brain activity patterns.

Wave Neuroscience partners with physicians, clinics, researchers, and healthcare organizations committed to advancing personalized mental healthcare and precision neuromodulation. Its partnership with Texas A&M Health and others will magnify the scope of its clinical and research portfolios.

Wave Neuroscience is improving brain function for the benefit of mental health. For more information, visit www.waveneuro.com.

Media Contact
Carly Scaduto
314-368-5189
[email protected]

SOURCE Ampa